High c-Myb Expression Associates with Good Prognosis in Colorectal Carcinoma

TICHÝ, Michal, Lucia KNOPFOVÁ, Jiří JARKOVSKÝ, Petr VLČEK, Jana KATOLICKÁ, Ivan ČAPOV, Markéta HERMANOVÁ, Jan ŠMARDA and Petr BENEŠ. High c-Myb Expression Associates with Good Prognosis in Colorectal Carcinoma. Journal of Cancer. Australia: IVYSPRING INT PUBL, vol. 10, No 6, p. 1393-1397. ISSN 1837-9664. doi:10.7150/jca.29530. 2019.

Basic information

• Original name: High c-Myb Expression Associates with Good Prognosis in Colorectal Carcinoma
• Authors: TICHÝ, Michal (203 Czech Republic, belonging to the institution), Lucia KNOPFOVÁ (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Petr VLČEK (203 Czech Republic), Jana KATOLICKÁ (203 Czech Republic), Ivan ČAPOV (203 Czech Republic), Markéta HERMANOVÁ (203 Czech Republic, belonging to the institution), Jan ŠMARDA (203 Czech Republic, belonging to the institution) and Petr BENEŠ (203 Czech Republic, guarantor, belonging to the institution).
• Edition: Journal of Cancer, Australia, IVYSPRING INT PUBL, 2019, 1837-9664.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30204 Oncology
• Country of publisher: Australia
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 3.565
• RIV identification code: RIV/00216224:14310/19:00107306
• Organization unit: Faculty of Science
• Doi: http://dx.doi.org/10.7150/jca.29530
• UT WoS: 000459711200007
• Keywords in English: c-Myb; colorectal cancer; prognosis; survival
• Tags: 14110112, 14119612, podil, rivok
• Tags: International impact, Reviewed

Abstract

Colorectal cancer (CRC) represents a serious challenge for oncologists due to high incidence and large heterogeneity. Prognostic factors are needed to stratify patients according to risk of disease progression. In this study, we report that high expression of c-Myb protein, determined by immunohistochemistry (IHC), associates with better overall and disease-free survival (OS, DFS) in a cohort of 103 patients. Although MYB has been previously considered to act as oncogene in CRC, our further analysis of datasets deposited in PrognoScan and SurvExpress databases confirmed that high MYB expression largely associates with good prognosis in CRC. As therapies targeting c-Myb have been developed and tested in preclinical studies, we believe that further studies are needed for detailed understanding of c-Myb function in CRC, before the c-Myb-targeted therapy enters clinical trials.

Links

• GJ17-08985Y, research and development project: Name: Prozánětlivá signalizace pod kontrolou proteinu c-Myb v bazálních prsních karcinomech

Investor: Czech Science Foundation

• NV18-07-00073, research and development project: Name: c-Myb a jeho transkripční program ve fyziologických a patologických osteogenních procesech

Investor: Ministry of Health of the CR